Minerva Neurosciences Inc (NERV) Receives Analyst Rating

Minerva Neurosciences Inc (NERV) : 1 brokerage houses believe that Minerva Neurosciences Inc (NERV) is a Strong Buy at current levels. Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 1 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.


Minerva Neurosciences Inc (NASDAQ:NERV): After opening at $12.98, the stock dipped to an intraday low of $12.9 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $14.14 and the buying power remained strong till the end. The stock closed at $13.88 for the day, a gain of 6.28% for the day session. The total traded volume was 706,432. The stocks close on the previous trading day was $13.06.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. Its lead product candidate is MIN-101, a compound for the potential treatment of patients with schizophrenia. Its product pipeline also includes MIN-117, MIN-202 and MIN-301. MIN-101 is a compound it is developing for the treatment of patients with schizophrenia. MIN-117 is a compound for the potential treatment of patients suffering from major depressive disorder (MDD). MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen for the treatment of insomnia. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinsons disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *